Sun Pharma arm acquires remaining 3.04 pc stake in PJSC Biosintez

By: |
Published: September 9, 2019 9:16:56 PM

Cash consideration of Rubles 54,194,628.60 equivalent to USD 815,201.99 (about Rs 6 crore) was paid to shareholders who tendered their respective shares in the mandatory tender offer, Sun Pharma said. Shares of Sun Pharmaceutical Industries on Monday closed at Rs 428.80 per scrip on the BSE, up 0.92 per cent from its previous close.

Shares of Sun Pharmaceutical Industries on Monday closed at Rs 428.80 per scrip on the BSE, up 0.92 per cent from its previous close.

Drug major Sun Pharmaceutical Industries on Monday said its Netherlands-based arm has fully acquired PJSC Biosintez, Russia by purchasing 3.04 per cent stake in the company under the mandatory tender offer. The company’s subsidiary — Sun Pharma (Netherlands) BV — already had 96.96 per cent stake in pharma firm PJSC Biosintez prior to the purchase of these shares, Sun Pharma said in a filing to the BSE. Post the purchase, Sun Pharma (Netherlands) BV’s shareholding in the target entity has increased from 96.96 per cent to 100 per cent, it added.

Cash consideration of Rubles 54,194,628.60 equivalent to USD 815,201.99 (about Rs 6 crore) was paid to shareholders who tendered their respective shares in the mandatory tender offer, Sun Pharma said. Shares of Sun Pharmaceutical Industries on Monday closed at Rs 428.80 per scrip on the BSE, up 0.92 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Patanjali’s success a lesson for Dabur; now, Ayurveda will be focus
2GST cheer for MSMEs: Small businesses to have more filing options in new return filing system
3PwC off the hook in Satyam scam as SEBI’s 2-year ban overturned by SAT